Transferosome: A Novel Transdermal Drug Delivery System for the Treatment of Hyperlipidemia
Published: 2023-11-15
Page: 318-326
Issue: 2023 - Volume 6 [Issue 2]
M. Ganga Raju *
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.
K. Venkata Srinija
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.
N. V. L. Suvarchala Reddy V.
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.
K. Keerthana
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.
P. Sravya
Department of Pharmacology, Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Telangana, India.
*Author to whom correspondence should be addressed.
Abstract
Hyperlipidemia describes a group of genetic along with medical conditions which raise cholesterol levels throughout the bloodstream. Many individuals suffer from this illness. It puts the patient at risk for major problems such heart disease, brain strokes, hepatic malfunction, and renal dysfunction. The barrier function of the skin usually restricts transdermal drug delivery, although it has evolved into a helpful strategy for therapeutic pharmacological compound administration. Transfersomes are ultradeformable nanovesicles made of lipid bilayer of phospholipids in conjugation with edge activator that surrounds an aqueous core. Transfersomes are mainly prepared by film hydration method, reverse-phase evaporation method, modified handshaking method, vortexing–sonication method, and ethanol injection method. By using an extremely deformable vesicular carrier to transfer bioactive chemicals through the skin more effectively, new potential and difficulties for the creation of innovative, enhanced therapeutics are presented. Since transfersomes are specifically optimized vesicles with the ability to respond to an external stress via quick and energy- efficient shape changes, it can solve all the issues with transdermal administration. Transfersomes have high entrapment efficiency and increase bioavailability. The use of transfersomes as a Transdermal delivery system for drugs with hyperlipidemia-active medication is part of an efficient treatment regimen for the hyperlipidemia disease.
Keywords: Transferosomes, transdermal delivery system, vesicular carrier, high entrapment efficiency, bioavailability, cerebral strokes, hyperlipidemia.
How to Cite
Downloads
References
Naser IH, Alkareem ZA, Mosa AU. Hyperlipidemia: pathophysiology, causes, complications, and treatment. A review. Karbala Journal of Pharmaceutical Sciences. 2021;1(19):118-132.
Shattat GF. A review article on Hyperlipidemia: types, treatments and new drug targets. Biomedical and Pharmacology Journal. 2015;7(1):399-409.
Witiak DT Newman HAI Feller DR. Antilipidemic Drugs: medicinal, chemical, and biochemical aspects. Elsevier; Distributors for the United States and Canada Elsevier Science Pub 1991.
Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of Hyperlipidemia. Bioorganic & medicinal chemistry. 2007;15(14):4674-99.
Tripathi KD. Essentials of medical pharmacology, 6th edn. India: JP Brother’s medical publishers. 2008:613-614.
Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007;119(2):370-80.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annual review of biochemistry. 2003; 72(1):137-74.
Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2003; 23(11):1463-74.
Rajan R, Jose S, Mukund VB, Vasudevan DT. Transferosomes-A vesicular Transdermal delivery system for enhanced drug permeation. Journal of advanced pharmaceutical Technology & Research. 2011;2(3):138.
Kodi SR, Reddy MS. Transferosomes: A Novel Topical Approach. Journal of Drug Delivery and Therapeutics. 2023;13(2): 126-31.
Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, Transdermal administration in ultra-deformable drug carriers, Transferosomes. Biochimica et biophysica acta (BBA)-biomembranes. 2001;1514(2):191-205.
Talegaonkar S, Mishra P, Khar R, et al. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68:141.
Prausnitz MR, Langer R. Transdermal drug delivery. Nature biotechnology. 2008;26 (11):1261-8.
Witika BA, Mweetwa LL, Tshiamo KO, Edler K, Matafwali SK, Ntemi PV, Chikukwa MT, Makoni PA. Vesicular drug delivery for the treatment of topical disorders: Current and future perspectives. Journal of Pharmacy and Pharmacology. 2021;73(11):1427-41.
Pawar AY. Transfersome: A novel technique which improves Transdermal permeability. Asian Journal of Pharmaceutics (AJP). 2016;10(04): S425-436.
Das B, Nayak AK, Mallick S. Transferosomes: a novel nanovesicular approach for drug delivery. In Systems of Nanovesicular Drug Delivery. Academic Press. 2022:103-114.
Opatha SA, Titapiwatanakun V, Chutoprapat R. Transferosomes: A promising nanoencapsulation technique for Transdermal drug delivery. Pharmaceutics. 2020;12(9):855.
Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. International journal of pharmaceutics. 2020;573:118817.
Jiang T, Wang T, Li T, Ma Y, Shen S, He B, Mo R. Enhanced Transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS nano. 2018;12(10):9693-701.
Rahmi AD, Pangesti DM. Comparison of the characteristics of transferosomes and protransferosomes containing azelaic acid. Journal of Young Pharmacists. 2018; 10(2s):S11.
Jain AK, Kumar F. Transferosomes: Ultra deformable vesicles for Transdermal drug delivery. Asian J. Biomater. Res. 2017;3:1-3.
Kotla NG, Chandrasekhar B, Rooney P, Sivaraman G, Larrañaga A, Krishna KV, Pandit A, Rochev Y. Biomimetic lipid-based nanosystems for enhanced dermal delivery of drugs and bioactive agents. ACS Biomaterials Science & Engineering. 2017;3(7):1262-72.
Ascenso A, Raposo S, Batista C, Cardoso P, Mendes T, Praça FG, Bentley MV, Simões S. Development, characterization, and skin delivery studies of related ultra deformable vesicles:transferosomes, ethosomes, and transethosomes. International Journal of Nanomedicine. 2015:5837-51.
Garg V, Singh H, Bimbrawh S, Kumar Singh S, Gulati M, Vaidya Y, Kaur P. Ethosomes and transferosomes: Principles, perspectives and practices. Current drug delivery. 2017;14(5):613-33.
Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. Transferosomes: a novel technique for Transdermal drug delivery. Journal of drug delivery and therapeutics. 2019;9(1):279-85.
Rajkumar J, Kumar AS, Shahnawaz GJ, Sushmitha A. Recent Update on Transferosomes as Transdermal Drug Delivery System. J Pharmacy and Drug Innovations. 2021;3(2).
Modi CD, Bharadia PD. Transferosomes: new dominants for Transdermal drug delivery. Am J Pharm Tech Res. 2012 ;2(3):71-91.
Prajapati ST, Patel CG, Patel CN. Transferosomes: A vesicular carrier system for transdermal drug delivery. Asian Journal of Biochemical and Pharmaceutical Research. 2011;2(1):507- 24.
Vinod KR, Kumar MS, Anbazhagan S, Sandhya S, Saikumar P, Rohit RT, Banji D. Critical issues related to transferosomes-novel vesicular system. ACTA Scientiarum Polonorum Technologia Alimentaria. 2012;11(1):67-82.
Sachan R, Parashar T, Soniya SV, Singh G, Tyagi S, Patel C, Gupta A. Drug carrier transferosomes: A novel tool for Transdermal drug delivery system. International Journal of Research and Development in Pharmacy and Life Sciences. 2013;2(2):309-16.
Hsiao SH, Chang HJ, Hsieh TH, Kao SM, Yeh PY, Wu TJ. Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review. Journal of clinical pharmacy and therapeutics. 2016;41(5): 575-8.
Zhou X, Mou Y, Shen X, Yang T, Liu J, Liu F, Dong J, Liao L. The role of atorvastatin on the restenosis process post-PTA in a diabetic rabbit model. BMC Cardiovascular Disorders. 2016;16:1-8.
Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clinical pharmacokinetics. 2003;42:1141-60.
Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug metabolism and disposition. 2006;34(7): 1175-81.
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238–25
Mahmoud MO, Aboud HM, Hassan AH, and Ali AA, Johnston TP. Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. Journal of controlled release. 2017; 254:10-22.
Jiang HY, Chen Y, Zhang H. Determination of Emodin in different products of radix sophorae flavescentis [J]. Chin Tradit Patent Med. 2001;23(3):185-7.
Lu K, Xie S, Han S, Zhang J, Chang X, Chao J, Huang Q, Yuan Q, Lin H, Xu L, Shen C. Preparation of a nano Emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. Journal of translational medicine. 2014;12(1):1-4.